Google
CLDI — CALIDI BIOTHERAPEUTICS INC. (Healthcare >> Biotechnology)
CLDI FAQ
What is CLDI's ROE?
CALIDI BIOTHERAPEUTICS INC. reports a Return on Equity (ROE) of -385.57%.
What is CLDI's dividend yield?
CALIDI BIOTHERAPEUTICS INC. offers a dividend yield of 0.00%.
What is CLDI's Deepscope Quality Score?
Deepscope rates CLDI's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy CLDI?
Deepscope's AI Timing Score for CLDI is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does CLDI belong to?
CALIDI BIOTHERAPEUTICS INC. is classified under the Healthcare >> Biotechnology sector on the NYSE MKT exchange.
|
USD 0.17
Price
-0.01
(-8.05%)
Day Change
|
|
|---|
CLDI, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 70 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.17 |
| PBV / Sector |
0.70 / 4.48
GREAT
|
| Earning Per Share | -0.91 |
| PE / Sector |
N/A / 16.68
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
0.51 M
GREAT
|
| Average 1W Daily Value |
0.77 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
43% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-04 09:23:28 |
| Symbol | CLDI |
| Name | CALIDI BIOTHERAPEUTICS INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NYSE MKT |
| Listed Shares | 19.31 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 3.48 / 8,483.11 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 4475 Executive Drive, San Diego, CA, United States, 92121
Phone: 858 794 9600
Website: https://www.calidibio.com
Sector: Healthcare >> Biotechnology
Description: Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as NeuroNova and SuperNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
